Skip to main content

Table 4 Adjusted cost ratios before and after the index date

From: Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States

 

Before index date

After index date

Healthcare resource

Cost ratioε

95% CI (ROBUST)

P value

Cost Ratioε

95% CI (ROBUST)

P value

Office visits

1.195

0.939 - 1.519

0.147

1.210

0.929 - 1.575

0.157

Outpatient visits

0.855

0.685 - 1.067

0.164

1.490

1.055 - 2.103

0.024

ER visits

0.844

0.627 - 1.136

0.263

1.160

0.830 - 1.624

0.386

Inpatient days

0.844

0.531 - 1.342

0.473

0.906

0.568 - 1.444

0.677

Other services

6.245

3.424 - 11.388

< 0.001

11.834

7.834 - 17.875

< 0.001

Prescription drugsω

0.995

0.782 - 1.267

0.970

1.372

1.087 - 1.731

0.008

  1. ε: Fully adjusted cost ratio; generalized Linear Model (gamma family, log link) adjusted for age category, gender, race, period of COPD diagnosis census region, oxygen use, Charlson Comorbidity Score, and interaction terms: AATD*CCI, AATD*Oxygen use and AATD*Period of COPD diagnosis
  2. Ï’: number of additional visits/IP days/Prescription drugs on a raw scale attributable to the presence of AATD; generalized linear model
  3. Ω: for a subset of patients who had prescription drug coverage through the same payer
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172